Previous 10 | Next 10 |
Ultragenyx (NASDAQ: RARE ) announces positive results from cohort 3 and longer-term data from cohort 2 in an ongoing Phase 1/2 clinical trial evaluating gene therapy DTX301 in patients with ornithine transcarbamylase deficiency. More news on: Ultragenyx Pharmaceutical Inc., Healthcare ...
More uniform response in Cohort 3 with two confirmed responders and one potential responder New female responder in Cohort 2 for a total of three confirmed female responders across all cohorts Up to six responders across all nine patients dosed in study Prophylactic steroid c...
NOVATO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief E...
Ultragenyx (NASDAQ: RARE ) inks an agreement with Royalty Pharma, agreeing to sell its royalty right in Europe from Kyowa Kirin Co., Ltd. from net sales of Crysvita (burosumab) for $320M. More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
NOVATO, Calif. and NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Royalty Pharma today announced that Ultragenyx has sold to R...
NOVATO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company’s Chief Financia...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2019 Q3 earnings Read more ...
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2019 Earnings Conference Call November 5, 2019, 05:00 PM ET Company Participants Danielle Keatley - Senior Director of IR and Corporate Communication Emil Kakkis - CEO and President Shalini Sharp - CFO Conference Call Participants Ge...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q3 GAAP EPS of -$1.96 misses by $0.28 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Strong Crysvita® (burosumab) Launch Continues with Approximately 1,130 Patients on Reimbursed Commercial Therapy in the United States as of the end of the Third Quarter UX007 (triheptanoin) NDA for Treatment of Long-chain Fatty Acid Oxidation Disorders Accepted for Review by FDA ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the develo...
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 ...